{"name":"Reistone Biopharma Company Limited","slug":"reistone-biopharma-company-limited","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Drug: SHR0302","genericName":"Drug: SHR0302","slug":"drug-shr0302","indication":"Type 2 diabetes","status":"phase_2"}]}],"pipeline":[{"name":"Drug: SHR0302","genericName":"Drug: SHR0302","slug":"drug-shr0302","phase":"phase_2","mechanism":"SHR0302 is a small molecule that targets the SGLT2 receptor.","indications":["Type 2 diabetes"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMivgJBVV95cUxPS2JoRlBodElWU0pveEtycWRlQ2RnQzRFb3Fwd0Z1amxhcklla0ZYR1Rkakh4Uzhvd3g3aHlrRDlWUUJ6UnFyejJkcU5YMUlyUnBVX2lYV3VsZDhyTV95bHpyRHVfc05VVl9mRjJJcXRkN1pxd3VEOE11S3FRNW9Vc1loYXVVMmdFcDN3UFM4Wkc2ajQ2dVY4Z0UyUVlublNXTEdvbnBrbnlPX2xLVi1wRFFId1JhNmNQSmtIWW1DSDNrNXl5WGZ6WWJEVjJfV2xLQVV0MUpjakk5enFVcmllQmZIbEl1RGZSUkVMQmFzS0FBMC1ZN2l3TXBxbW5GaG1HY3QxZlE1Z21ERTJjZHo5NUtTSmtONDJoWUpoTWRTc3A3ek53SUo5ckVEbElDYUFSZTNtUUNVUmh5cU5UVkE?oc=5","date":"2026-02-19","type":"pipeline","source":"PR Newswire UK","summary":"Alopecia Areata Market Set to Expand by 2036, Due to the Emergence of Novel Drug Classes Such as OX40L Inhibitors, IL-2 Inhibitors, IL-7Rα, and Others | DelveInsight - PR Newswire UK","headline":"Alopecia Areata Market Set to Expand by 2036, Due to the Emergence of Novel Drug Classes Such as OX40L Inhibitors, IL-2 ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijwJBVV95cUxPVnZGYTBfR3o4czAtRFJXU1dwX190aXBvd3dCVUhxUnZXekRSeDR1TmN4ZkpHZWhVSlVBcWNVNXlXYmVQamUzWm9UR0hfY0pkaDNzV0NPdGV1aXFDREEzTGZTOUk0aEppbk9GUGs5b3R6MGdOOHR4djRLTkh2OW1Ub2t0dGh6SUV5VEctOFpOTzRHb05OSmRSVUQzRjhOOEZpZ3hfQ1hONzk0dm9xeEZqeTczSFBoWjllakRONGEzRzI1RDAxMlF6NmM3b0JYajJBWG1oU3dPczFZTkt6a3ZFeU5ER1pkZ0t6S21KVnUzVjhfRV9qRGJNb01HNkVUSVNIV0pmdEU4YU9fcGJBWmU0?oc=5","date":"2026-02-16","type":"pipeline","source":"PR Newswire","summary":"Atopic Dermatitis Market to Accelerate at a Rapid Pace by 2034 with Advancements in Biologics and JAK Inhibitors | DelveInsight - PR Newswire","headline":"Atopic Dermatitis Market to Accelerate at a Rapid Pace by 2034 with Advancements in Biologics and JAK Inhibitors | Delve","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMingJBVV95cUxQdEFnQktFM210eXdiZmRhVlE4Y3FUTndfak5Cell5OFgyR1Z1QWxsaks4TzU0NTBvZlJIc0o3enpwWTlTYXBFR3o4eFZNZUg2QUpEZGN5Z3ZsTFRqTmZOMVBSZVpoa1YxT3ZHbFlaVVJOZHBWZjFkSE1jSFpXSVVpYVl2U1VhSHRJS1daVHZkSHAtLW5nbW1aeWZIZk9CQUxLNnVlYVF6VVZNRVdtT3ZpVzhMVkI1ODFPLUpqLWpBU3dEVnpWSldBX1JaTmZaX1VTUFJEc0hubWtXZGVwWmw4UmlyLUpTbk5MYVhCRENwaVByRVhzZXhobF9wUGJNYzUtMGNzWEFqbkN3enFKdFplVjJnYzVPQVduMDAzZ1Jn?oc=5","date":"2025-12-08","type":"regulatory","source":"GlobeNewswire","summary":"Eczema Clinical Trial Pipeline Accelerates as 100+ Pharma - GlobeNewswire","headline":"Eczema Clinical Trial Pipeline Accelerates as 100+ Pharma","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirgJBVV95cUxNbURGeFBVM19lWjJINGlwR01HamQ5X2traTA5bllxU0gyWkd6M21MeElyZXhHTzR2LUhvZ0tsbmNzZXVoVFp0bTc0a1pNZmxDaDFNTkxXT2RWNVpYZG5CZWpBYWNGNTVPVUVGQzJwYUY2YWpTb2hWMGJDSU5tUE9OMmlHOHNScHZDM3ZZRE5YXzFRTXZzT1BkYVFKWUlNN2g1YTh1aHJKN1h3eTJ2cTFFdzdVbnVHV05EWDQ0SVB6VEZDOFdkQzU2QUhyQXRXT3BmbDY0eDllY0R6LUhNaHo0dkU0dWtNUjJ5OGFteEdSUzM4SWlZVVRnX2ZDUWFMZmRKVmZXRllhZDNHN3QzLVRabWZERlhTV0JCTWdaQ1JUdmpqbkY5OHpNb053SUdRUQ?oc=5","date":"2025-10-23","type":"trial","source":"GlobeNewswire","summary":"Hidradenitis Suppurativa Clinical Trial Analysis: Key - GlobeNewswire","headline":"Hidradenitis Suppurativa Clinical Trial Analysis: Key","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi7AFBVV95cUxQbGdvVFdOQkQyQ016WmtQQ2ZTRU81cWE1VnFFNnFMd2t5bU41Nzh6UURXcVk1YkRHWGkxYlFsMzU1U3VKYnBobGgxSUNBRXZ2VmZiaXhqUnRsclhZbTBIVURxSlF0UmZDM3I4R2E2M0pqcUdSRTdDdDlJdi16QjBCZWU2SzJlalVnXzd1M2kyVFVBaDZ0Rmp1ZlBDeEUtY0FSOHUzN1hiSjAtSWdXN1NWQnZDTE9nbXJGb1VSUkdEQmJFV1ZTcTRkb3lVMVFkcWJyM1ljQTBYSWh1M3BwaTBoMFFVYWJuRHNTYlNjNA?oc=5","date":"2025-04-15","type":"pipeline","source":"PR Newswire UK","summary":"Takeda's ENTYVIO Continues Growth Trajectory in Ulcerative Colitis and Crohn's Disease | DelveInsight - PR Newswire UK","headline":"Takeda's ENTYVIO Continues Growth Trajectory in Ulcerative Colitis and Crohn's Disease | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiyAJBVV95cUxQT0pkMkxEYXAzQmNNOEFLNkN1S1RaazBYUGdNS29VVjNDeXotZEpuUGRKSURyQi1LY1dhWGJvcnJ1d2s0VEw4ZUhSSDNCZTBmZzJxcWJrUkdycUpuV0lmOEFNakFpT2otaEcyLWZlX0F6cVV1Q0dxczZXY0VJbUYzVTFlR2dHYkExTXFzdnYxZ3ZlZWpBV2xSamFXcklJejNFQmhvQ2RTT2ZwLU9meXoxa1dGQ2ZwTzZZRHRzR1d4OFE4WXctVzFPWHBQZi1MYXl6NENOTGxmWG53eWdDYVUwM2lhQVBIM04zRnhfUVE1dVE0dG5WUnNzaTF4X2hyUXhwekFkT1hjakRJUTFLNVNGcmRrN2xwMnNfX0dTdnEwSXowRFExOGY1NkNOalJieDFtRVhnTzFlMHQwUUZ3S1pSWXNSNERvZUtx?oc=5","date":"2025-03-03","type":"trial","source":"GlobeNewswire","summary":"JAK Inhibitors Clinical Trial Pipeline Appears Robust With - GlobeNewswire","headline":"JAK Inhibitors Clinical Trial Pipeline Appears Robust With","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqwJBVV95cUxOenZwWnVZZTJIRTVqNlF5cEJwZHhzWGFMay1aYVVsN2l3b3BEWHpkYU5VN1BJSlhYa2kzMlAwZ09EMFJEZXdTNXJzajVYLVdZWUJrRHAza3ZreGY1UlRNaWUwYUl0cEQ2NFJPMEJJelFoWWYxMWRZOVE3UmQydDRQRk5oVTloaEdhUEZCVXJPZmpGSEVPcWZ6ZFBueTdOdmlpSDVJQmVhZkVkWVByNEZETGxPc1lBNXFKanpRWllUaHVWZTJmRVR5aDlVelpvYXk4LWpPT2hmZFVOOWV4Z1Q0cEVZUDBINEk2QVpsWDFCOERfQmxMWnQwQlloT3NoVGVsTnA2NXQ5VHVjRDhBdjctTUw1bmFFT0xwclJSQ2QwdE1CUFMtV3JsbW1PTQ?oc=5","date":"2024-10-22","type":"trial","source":"PR Newswire","summary":"JAK Inhibitors Clinical Trial Pipeline Experiences Momentum: DelveInsight Estimates a Diverse Pipeline Comprising 50+ Companies Working in the Domain - PR Newswire","headline":"JAK Inhibitors Clinical Trial Pipeline Experiences Momentum: DelveInsight Estimates a Diverse Pipeline Comprising 50+ Co","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimwJBVV95cUxNMVBaRmxTUlZYYlVWSDVjcTktZFljZjFfcE9VbDlMR29mYUNmdGhENU1KMTRoVG1NcnVtUVphMnJuMXB0V0tCb1ZGVFZIOVFPMDBjQ3NNTC1ETWdnOFJGTy12Y2VJM1VLbDZzYlQ0bmlGRlhBb0Y0dlpPZ2hwb213TW01Z1RETzBBTU9vbFdtcjhaZHdMZERpbWlRQ0dCa2c1SVB2MXVkWjJrSXk5V0Z4Z1VneTlreEFEX0h2dW54NGpnRGt0a29fLW5xZEZoMDg4V0dDRGhvMDV1Q3hmQTlNcmJieVBmTEdoRXlvZ0hvcXdqbDdFazdMSGEwSU4yQkFGdVg4R1Nla3lXQ19hOUtwX0lJZVlBLTFVQkpF?oc=5","date":"2024-07-15","type":"regulatory","source":"PR Newswire","summary":"SKYRIZI's Approval For Ulcerative Colitis Treatment Expands AbbVie's Portfolio Across Immune-mediated Inflammatory Diseases | DelveInsight - PR Newswire","headline":"SKYRIZI's Approval For Ulcerative Colitis Treatment Expands AbbVie's Portfolio Across Immune-mediated Inflammatory Disea","sentiment":"positive"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_2":1},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}